NeoStem (NBS) announces a public offering, saying it intends to use the proceeds for working...

NeoStem (NBS) announces a public offering, saying it intends to use the proceeds for working capital, including research and development of cell therapeutic product candidates, including AMR-001, plus expansion of its business units, strategic transactions and other general corporate purposes. Terms and size of the offering have not yet been disclosed. Aegis Capital is acting as sole book-running manager. Shares -8% AH.

Comments (3)
  • theomeo
    , contributor
    Comments (14) | Send Message
    Clearly burning capital and offering will increase dilution. Great business model but clearly not good enough to bring in business re working with other trails for profit.
    29 Apr 2013, 08:36 PM Reply Like
  • Noreika
    , contributor
    Comments (497) | Send Message
    That's why I just sit on the sidelines for now Theo. They're dilution machines!
    29 Apr 2013, 09:33 PM Reply Like
  • Thack
    , contributor
    Comments (3) | Send Message
    NBS will increase it's value. AMR-100 has the potential to greatly increase the value of NBS. When you invest in microbiology, it's very important to gain an understanding of the clinical value of the products produced. Without that, it's just like playing the lottery.
    30 Apr 2013, 12:48 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs